BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25464010)

  • 1. PDE and cognitive processing: beyond the memory domain.
    Heckman PR; Blokland A; Ramaekers J; Prickaerts J
    Neurobiol Learn Mem; 2015 Mar; 119():108-22. PubMed ID: 25464010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats.
    Rutten K; Van Donkelaar EL; Ferrington L; Blokland A; Bollen E; Steinbusch HW; Kelly PA; Prickaerts JH
    Neuropsychopharmacology; 2009 Jul; 34(8):1914-25. PubMed ID: 19262466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
    Guo L; Luo L; Ju R; Chen C; Zhu L; Li J; Yu X; Ye C; Zhang D
    Eur J Pharmacol; 2015 Jan; 746():14-21. PubMed ID: 25446933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Prickaerts J; Heckman PRA; Blokland A
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1033-1048. PubMed ID: 28772081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview.
    Heckman PR; Wouters C; Prickaerts J
    Curr Pharm Des; 2015; 21(3):317-31. PubMed ID: 25159073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Object memory enhancement by combining sub-efficacious doses of specific phosphodiesterase inhibitors.
    Bollen E; Akkerman S; Puzzo D; Gulisano W; Palmeri A; D'Hooge R; Balschun D; Steinbusch HW; Blokland A; Prickaerts J
    Neuropharmacology; 2015 Aug; 95():361-6. PubMed ID: 25896769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer's Disease.
    Sharma VK; Singh TG; Singh S
    Curr Drug Targets; 2020; 21(13):1371-1384. PubMed ID: 32718286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross talk between NO and cyclic nucleotide phosphodiesterases in the modulation of signal transduction in blood vessel.
    Lugnier C; Keravis T; Eckly-Michel A
    J Physiol Pharmacol; 1999 Dec; 50(4):639-52. PubMed ID: 10639014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
    Xi M; Sun T; Chai S; Xie M; Chen S; Deng L; Du K; Shen R; Sun H
    Eur J Med Chem; 2022 Mar; 232():114170. PubMed ID: 35144038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterases in the central nervous system.
    Kleppisch T
    Handb Exp Pharmacol; 2009; (191):71-92. PubMed ID: 19089326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving memory: a role for phosphodiesterases.
    Blokland A; Schreiber R; Prickaerts J
    Curr Pharm Des; 2006; 12(20):2511-23. PubMed ID: 16842174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herbs to curb cyclic nucleotide phosphodiesterase and their potential role in Alzheimer's disease.
    Kumar A; Sharma V; Singh VP; Kaundal M; Gupta MK; Bariwal J; Deshmukh R
    Mech Ageing Dev; 2015 Jul; 149():75-87. PubMed ID: 26050556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis.
    Kyoi T; Oka M; Noda K; Ukai Y
    Life Sci; 2004 Aug; 75(15):1833-42. PubMed ID: 15302227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of various phosphodiesterase-inhibitors, forskolin, and sodium nitroprusside on porcine detrusor smooth muscle tonic responses to muscarinergic stimulation and cyclic nucleotide levels in vitro.
    Truss MC; Uckert S; Stief CG; Kuczyk M; Schulz-Knappe P; Forssmann WG; Jonas U
    Neurourol Urodyn; 1996; 15(1):59-70. PubMed ID: 8696357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.
    Kleiman RJ; Chapin DS; Christoffersen C; Freeman J; Fonseca KR; Geoghegan KF; Grimwood S; Guanowsky V; Hajós M; Harms JF; Helal CJ; Hoffmann WE; Kocan GP; Majchrzak MJ; McGinnis D; McLean S; Menniti FS; Nelson F; Roof R; Schmidt AW; Seymour PA; Stephenson DT; Tingley FD; Vanase-Frawley M; Verhoest PR; Schmidt CJ
    J Pharmacol Exp Ther; 2012 May; 341(2):396-409. PubMed ID: 22328573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase II, the cGMP-activatable cyclic nucleotide phosphodiesterase, regulates cyclic AMP metabolism in PC12 cells.
    Whalin ME; Scammell JG; Strada SJ; Thompson WJ
    Mol Pharmacol; 1991 Jun; 39(6):711-7. PubMed ID: 1646946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4).
    Bivalacqua TJ; Champion HC; Rajasekaran M; Sikka SC; Kadowitz PJ; Doherty PC; Hellstrom WJ
    J Urol; 1999 Nov; 162(5):1848-55. PubMed ID: 10524946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial biochemical and functional characterization of cyclic nucleotide phosphodiesterase isozymes in canine colonic smooth muscle.
    Barnette MS; Manning CD; Price WJ; Barone FC
    J Pharmacol Exp Ther; 1993 Feb; 264(2):801-12. PubMed ID: 7679736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
    Wu Y; Li Z; Huang YY; Wu D; Luo HB
    J Med Chem; 2018 Jul; 61(13):5467-5483. PubMed ID: 29363967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.